- SID Score
- 8.1/10
- Fair value
- $296.13
- Generated
- Nov 1, 2026
- Model
- claude-haiku-4-5-20251001
Johnson & Johnson trades at $273.20 with a market capitalization of $505.8 billion and demonstrates solid fundamental strength with a SID Score of 8.1/10. The stock exhibits a compelling 8.4% upside to its fair value estimate of $296.13, though the analyst consensus price target of $207.08 appears significantly disconnected from current valuations. With consistent earnings beats and positive momentum indicators, JNJ presents a balanced risk-reward profile for healthcare-focused investors seeking stable exposure to a diversified pharmaceutical and consumer health leader.
JNJ's valuation metrics reveal a company trading at a P/E ratio of 20.30, which is reasonable for a healthcare sector leader with consistent profitability and revenue streams. The company's recent earnings demonstrate steady performance, with three consecutive beats over the past four quarters, most notably a $2.90 EPS actual versus $2.85 estimated in Q2 2026. However, the notably low dividend yield of 0.02% contradicts JNJ's traditional reputation as a dividend aristocrat, suggesting either a data anomaly or significant recent capital reallocation decisions. The Factor Grades present a mixed picture, with strong Growth (A) and solid Profitability (C) ratings, though the Value grade (D) indicates the stock may be fairly to moderately overvalued relative to peers.
The stock displays constructive technical positioning with an RSI(14) of 58.0, indicating neither overbought nor oversold conditions and suggesting room for further upside movement. Price action shows positive momentum with the current price of $273.20 trading above both the 50-day moving average ($265.60) and 200-day moving average ($248.51), confirming an uptrend intact over multiple timeframes. The $24.62 gap between the current price and the 50-day MA represents only a 2.9% premium, suggesting the stock has not extended too far from intermediate support levels and maintains healthy technical structure.
Analyst & Insider Sentiment
Insider activity presents a bullish divergence, with three executives (Woods, Pinto, and Hewson) collectively purchasing 430 shares on September 8, 2026, demonstrating confidence in the company's direction despite recent market volatility. Conversely, Timothy Schmid executed substantial sales totaling 33,597 shares on September 2, 2026, which may represent portfolio rebalancing or predetermined trading plans rather than negative sentiment. The analyst consensus rating of "Buy" with an average price target of $207.08 appears questionable given the current price of $273.20, suggesting significant analyst estimate revisions or data timing discrepancies that warrant clarification.
The most significant risk is the substantial disconnect between the $207.08 analyst consensus price target and the current trading price of $273.20, representing a 24% downside if the consensus proves accurate; this wide gap suggests either outdated analyst data or potential overvaluation concerns. Healthcare regulatory risks, pharmaceutical pricing pressures, and patent cliff challenges for key drug portfolios represent ongoing sectoral headwinds that could impact earnings growth trajectories. The neutral news sentiment combined with limited recent financial data availability constrains the ability to assess emerging operational challenges or positive catalysts that could drive near-term performance.
Johnson & Johnson represents a quality healthcare dividend play suitable for conservative investors seeking exposure to a market-leading pharmaceutical conglomerate with demonstrated earnings consistency and technical strength. The 8.4% upside to fair value ($296.13) combined with the company's strong Growth factor grade (A) and insider buying support a cautiously optimistic near-term outlook, particularly for buy-and-hold investors with multi-year horizons. However, prospective investors should exercise caution given the questionable analyst consensus target and verify dividend sustainability before accumulating positions, using any dips toward $265-$270 as potential entry points with favorable risk-reward dynamics.
